Saint-Prex, Switzerland
July 03, 2018
:
Ferring Pharmaceuticals announced new data demonstrating that its heat-stable formulation of carbetocin is as effective as the current standard of care, oxytocin, for the prevention of excessive bleeding, also known as postpartum haemorrhage (PPH),after vaginal birth.
Berlin, Germany & Nevada, USA
July 03, 2018
:
MagForce AG, a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. has announced MagForce USA has enrolled the first patient
Shanghai
July 02, 2018
:
I-Mab Biopharma, a company focusing on innovative Biologics in therapeutic areas of immuno-oncology and immuno-inflammation, announced the completion of Series C financing for US$ 220 million
Jena, Germany
July 02, 2018
:
InflaRx N.V., a biopharmaceutical company developing innovative therapeutics to treat life-threatening inflammatory diseases by targeting the complement system, a key component of the innate immune system
Berlin, Germany
July 02, 2018
:
Noxxon Pharma N.V., a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that patient recruitment is almost complete in its ongoing clinical trial
Our Bureau, Mumbai
June 30, 2018
:
Industry leaders Dr. Rhonda Paz, PhD, and Shirley Trainor-Thomas have launched Next Phase Clinical Research, which is a client-centric company focused on research infrastructure development for operational and
Vienna
June 30, 2018
:
After a four and a half year battle, a decision has been delivered by the arbitrator in Cel-Sci Corporation's arbitration suit against clinical development giant inVentiv, now part of Syneos Health. The arbitrator
Staines-upon-thames, UK
June 30, 2018
:
Mallinckrodt plc, a leading global specialty pharmaceutical company, announced it has completed enrollment of the company's ongoing Phase 4 clinical trial of HP Acthar Gel for Rheumatoid Arthritis (RA) patients.
Stockholm
June 29, 2018
:
Medivir AB has announced positive top-line results from the MIV-711 phase IIa extension study (MIV-711-202). The study met the primary endpoint, demonstrating that MIV-711 200mg had an acceptable safety
New Haven, Conn
June 29, 2018
:
Biohaven Pharmaceutical Holding Company Ltd. is presenting expanded data from two randomized, pivotal Phase 3 clinical trials of rimegepant, Biohaven's small molecule calcitonin gene-related peptide (CGRP)